×
About 16,825 results

ALLMedicine™ Chronic Myeloid Leukemia Center

Research & Reviews  7,791 results

Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities an...
https://doi.org/10.1016/j.clml.2021.01.020
Clinical Lymphoma, Myeloma & Leukemia; Shin H, Ha JE et. al.

Feb 26th, 2021 - Dasatinib is administered at a fixed starting dosage of 100 mg once daily regardless of patient-specific factors. However, such fixed dosing may not be optimal for the treatment of Asian patients with chronic myeloid leukemia in chronic phase (CP-...

Adverse events associated with nilotinib in chronic myeloid leukaemia: mechanisms and m...
https://doi.org/10.1080/17512433.2021.1894129
Expert Review of Clinical Pharmacology; Wang Z, Jiang L et. al.

Feb 23rd, 2021 - Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly-diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients who are re...

BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemi...
https://doi.org/10.2174/1574892816666210222152126
Recent Patents on Anti-cancer Drug Discovery; Hailemariam TS, Mehdi M et. al.

Feb 23rd, 2021 - Chronic myeloid leukemia is characterized by the presence of Phila¬delphia chromosome, which caused by the breakpoint cluster region-Abelson fusion or joined gene. High concentration of BCR-ABL transcripts level can strongly forecast cytogenetic a...

Underreporting of symptomatic adverse events in phase I clinical trials.
https://doi.org/10.1093/jnci/djab015
Journal of the National Cancer Institute; Veitch ZW, Shepshelovich D et. al.

Feb 22nd, 2021 - At diagnosis of chronic-phase chronic myeloid leukemia (CML), there are conflicting data as to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia (Ph) translocation confer a higher risk of subsequent disease progres...

Bosutinib in the Real-Life Treatment of Chronic Myeloid Leukemia Patients Aged > 65 Yea...
https://doi.org/10.1002/hon.2851
Hematological Oncology; Latagliata R, Attolico I et. al.

Feb 22nd, 2021 - To evaluate the role of bosutinib in elderly patients aged > 65 years with chronic myeloid leukemia (CML), a real-life cohort of 101 chronic phase CML patients followed up in 23 Italian centers and treated with bosutinib in 2nd or a subsequent lin...

see more →

Guidelines  15 results

Not Just Another App: Realizing the Potential of Mobile Healthcare Applications to Promote Adherence to Oral Cancer Therapy Medications
https://jnccn.org/view/journals/jnccn/18/2/article-p219.xml
JNCCN Wen KY

Jan 31st, 2020 - Oral cancer therapy agents are changing the treatment paradigm in oncology. In the past decade, the number of adult patients with cancer receiving oral cancer therapies has increased dramatically. Oral cancer therapies offer convenience to patient...

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
http://www.bio-rad.com/en-us/corporate/newsroom/bio-rad-releases-first-fda-cleared-digital-pcr-system-test-for-monitoring-chronic-myeloid-leukemia-treatment-response?ID=Bio-Rad-Releases-Fir_1550252610

Feb 13th, 2019 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-AB...

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/9/1108.full
Radich, J.

Aug 31st, 2018 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendati...
https://doi.org/10.1002/cncr.31411
Cancer Rea D, Ame S et. al.

May 3rd, 2018 - The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is...

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://academic.oup.com/annonc/article/28/suppl_4/iv41/3958153
Hochhaus, A.

Jul 12th, 2017 - The incidence of chronic myeloid leukaemia (CML) ranges between 10 and 15 cases/106/year without any major geographic or ethnic differences [1]. The median age at diagnosis ranges between 60 and 65?years in Europe, but is considerably lower in cou.

see more →

Drugs  91 results see all →

Clinicaltrials.gov  8,331 results

Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities an...
https://doi.org/10.1016/j.clml.2021.01.020
Clinical Lymphoma, Myeloma & Leukemia; Shin H, Ha JE et. al.

Feb 26th, 2021 - Dasatinib is administered at a fixed starting dosage of 100 mg once daily regardless of patient-specific factors. However, such fixed dosing may not be optimal for the treatment of Asian patients with chronic myeloid leukemia in chronic phase (CP-...

Study Finds Asciminib Safer, More Effective Than Bosutinib in Chronic-Phase CML
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/study-finds-asciminib-safer-more-effective-than-bosutinib-in-chronic-phase-cml/

Feb 24th, 2021 - Since the introduction of imatinib almost 18 years ago, similar next-generation tyrosine kinase inhibitors have been approved for chronic myeloid leukemia (CML), including dasatinib, nilotinib, bosutinib, and ponatinib. These drugs attack a simila...

Adverse events associated with nilotinib in chronic myeloid leukaemia: mechanisms and m...
https://doi.org/10.1080/17512433.2021.1894129
Expert Review of Clinical Pharmacology; Wang Z, Jiang L et. al.

Feb 23rd, 2021 - Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly-diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients who are re...

BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemi...
https://doi.org/10.2174/1574892816666210222152126
Recent Patents on Anti-cancer Drug Discovery; Hailemariam TS, Mehdi M et. al.

Feb 23rd, 2021 - Chronic myeloid leukemia is characterized by the presence of Phila¬delphia chromosome, which caused by the breakpoint cluster region-Abelson fusion or joined gene. High concentration of BCR-ABL transcripts level can strongly forecast cytogenetic a...

Underreporting of symptomatic adverse events in phase I clinical trials.
https://doi.org/10.1093/jnci/djab015
Journal of the National Cancer Institute; Veitch ZW, Shepshelovich D et. al.

Feb 22nd, 2021 - At diagnosis of chronic-phase chronic myeloid leukemia (CML), there are conflicting data as to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia (Ph) translocation confer a higher risk of subsequent disease progres...

see more →

News  593 results

On the Horizon: Asciminib, a New Drug for Treating R/R CML
https://www.medscape.com/viewarticle/942607

Dec 13th, 2020 - The investigational drug asciminib (being developed by Novartis) may become the new kid on the block for the treatment of chronic phase chronic myeloid leukemia (CMP-CP) for patients who have relapsed on or are refractory to at least two prior tyr...

Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes
https://www.medscape.com/viewarticle/941633

Nov 25th, 2020 - NEW YORK (Reuters Health) - In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported outcomes, a nonrandomized trial reveals. "Consider treatment dis...

Are We Close to Predicting Treatment-Free Remission in CML?
https://www.staging.medscape.com/viewarticle/941327

Nov 18th, 2020 - A recent study in the British Journal of Haematology by Irani and colleagues suggests that an effector-suppressor score, which is calculated using absolute natural killer (NK) cell, FoxP3+ regulatory T-cell (T-reg), and monocytic myeloid-derived s...

Are We Close to Predicting Treatment-Free Remission in CML?
https://www.medscape.com/viewarticle/941327

Nov 18th, 2020 - A recent study in the British Journal of Haematology by Irani and colleagues suggests that an effector-suppressor score, which is calculated using absolute natural killer (NK) cell, FoxP3+ regulatory T-cell (T-reg), and monocytic myeloid-derived s...

Clinical Practice Guidelines on Chronic Myeloid Leukemia (NCCN, 2020)
https://reference.medscape.com/viewarticle/939995

Oct 29th, 2020 - In October 2020, the National Comprehensive Cancer Network (NCCN) released an updated version of its clinical practice guidelines on chronic myeloid leukemia (CML), including on diagnosis and workup, management of chronic-phase CML (CP-CML), and C...

see more →

Patient Education  4 results see all →